This appendix summarizes changes we made to include IPV in the India model, [16,17] and provides supplemental results. We use the same acronyms and we refer to the tables and figures in the main paper here. We also provide additional tables and figures preceded by an "A" to distinguish them from those in the main text. The IPV scenarios include potential administration of a dose of OPV and IPV at the same time in RI. Due to limited information available on seroconversion rates of IPV for northern India, we relied on the results of recent reviews (see Table 1 ). [5,19] 
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Notation
We define the following and refer to Duintjer Tebbens et al. (2013) [16] for further details on these quantities and their place within the full set of model equations: Indices a = model age group (a = 0,…, na-1, where na=8 and age group 0 represents infants from 0-2 months, inclusive (maternally immune infants only exist in age group 0) e = excretion and transmission mode (e = 0 (fecal) or 1 (oropharyngeal)) i = immunity state (i = 0 (fully susceptible), 1 (maternally immune), 2 (1 successful IPV), 3 (2 successful IPV, 4 (≥ 3 successful IPV), 5 (1 LPV infection), 6 (≥ 2 LPV infections),7 (IPV and LPV)) j = virus strain (j = 0 (OPV), 1,…, h-2 (OPV-related), h-1 (FRPV), h (WPV), where h=20) k = infection stage (k = 0 (first latent stage), r-1(last latent stage), r (first infectious stage), …, r+s-1 (last infectious stage), where r=2 and s=4) w = waning stage (w = 0 (recent),…, nw -1, where nw=5; note that fully susceptibles and maternally immunes only exists in waning stage 0)
Symbols for state variables
IPVEa,i,w = successfully IPV-vaccinated individuals from immunity state i, age group a, and waning stage w yet to acquire the properties of the next IPV state (i.e., IPV-exposed individuals) LIa,i,w,j,k,e = σi,w = relative susceptibility for immunity state i in waning stage w wa = width of age group a (with w0 = ρMI = 0.25×365 days) [day] ξi,w,e = duration of latent period for immunity state i, waning stage w, and excretion mode e [day] , , , , ,
, , , , ,
Use of three IPV doses in RI
Similar to RI with OPV, we assume that primary (non-birth) RI with IPV occurs at the time that infants age from the maternally immune 0 to 2-month age group into the 3 to 11-month age group. We model the cumulative effect of the 3 primary doses and all possible combinations of priming, taking, or remaining susceptible after each dose. Thus, previously fully susceptible (FS) or maternally immune (MI) individuals vaccinated with IPV may remain FS or MI, or move to the 1 successful IPV state (IPV1, i.e., primed), 2 successful IVP state (IPV2), ≥3 successful IPV state (IPV3) following an effective "take" with 0, 1, 2, or 3 IPV doses, respectively (Table  A1) . We assume a cumulative take rate after three doses of IPV of 0.95 for the base case and probabilities p1 of priming, p2 of "take" given one successful prior IPV dose, and p3 of "take" given two successful prior IPV doses equal to the average per-dose take rate 1  1  1  1  1  2  3  1  1  2  1  1  1  1  2  1  1  1   2  2  1  2  3  1  1  1  2  1  1  2  2  1  2  1  3   3  3  1  2  3 where dcovi represents the proportion of children receiving exactly i (non-birth) RI doses. We assume that any number of successful IPV doses move previously immune individuals (i.e., individuals with 1 or more prior LPV infections, because no IPV-immunes do exist in the model prior to the age of RI IPV vaccination) to the IPV and LPV immunity state, which we model with the same properties as the ≥ 2 LPV infections immunity state. [16, 17] 
Use of one IPV dose in RI added to three non-birth OPV doses
We model the cumulative effect of an added IPV dose to the 3 primary OPV doses as a boost in take by one IPV dose. We use the average per-dose IPV take rate ( ) of 0.63 to calculate the combined per dose take rates similar to the methods used for OPV based on the cumulative take rate after 3 doses (i.e., trd=1-(1-tr) d , for d doses and an average per-dose take rate equal to tr). As above, we consider the coverage of individuals vaccinated with 1, 2 or 3 primary OPV doses to estimate the take rate for a simultaneous OPV and IPV third dose assuming: tr 1 1 1 tr . We assume that children receive IPV simultaneously with the first non-birth OPV dose that they receive (regardless of the age at which they receive the first OPV dose), so that any child receiving at least one non-birth OPV dose also receives the added IPV dose. The effective vaccination coverage for fully susceptible and maternally immune individuals becomes:
, where 
Use of a IPV dose in RI instead of the third non-birth OPV dose
We assume that infants receive the immunity from any OPV and IPV they receive as they age into the 3-11 month age group. We model the cumulative effect of 2 primary OPV doses in the same way as three cumulative doses, except with the coverage of third OPV dose (dcov3) equal to 0 (i.e., we replace the third OPV dose with an IPV dose). We use the average per-dose IPV take rate (tr IPV ) of 0.63 to calculate the effect of the one IPV dose assuming vaccine recipients get this dose at the same coverage level as the coverage of the third OPV dose. Thus, previously fully susceptible or maternally immune individuals vaccinated with that IPV dose may remain fully susceptible or maternally immune, or move to the 1 IPV state (primed) with 1 3 1. Previously LPV-immune individuals move to the IPV and LPV immunity state at the average per-dose take rate, without multiplication by relative susceptibility, consistent with the assumption that IPV doses boost immunes at the same rate that they prime susceptible individuals.
Gradually replace non-birth OPV doses with IPV in RI
We assume that infants receive the immunity from any OPV and IPV doses that they receive as they age into the 3-11-month age group. We replace 3 primary OPV doses with one IPV dose per year. For the first replacement, we use the approach for one IPV dose instead of the third non-birth OPV dose described above. For the second replacement, we model the effect of one OPV dose as 1 followed by two IPV doses: using an IPV dose instead of the second OPV dose with coverage dcov2, and using a second IPV dose instead of the third OPV dose with coverage dcov3. Thus, previously fully susceptible or maternally immune individuals vaccinated with IPV may remain fully susceptible or maternally immune, or move to the 1 IPV state (primed) or 2 IVP state following an effective "take" with 0, 1, or 2 IPV doses respectively: 1 2 , where 1 1 1 2 1 1 1 1 1 2 and 2 2 1 2 . As above, LPV-immunes move to the IPV and LPV immunity state following IPV at the appropriate rates. For the final replacement of the last dose, we follow the approach for the use of three IPV doses in RI described above.
Additional results
Figures A1 and A2 show the results comparable to Figures 1 and 2 for WUP. Figure A3 shows the results for both areas for all three serotypes for the scenarios shown in Figure 3a . Figure A4 shows the results for both areas for all three serotypes for the scenarios shown in Figure 3b . Figure A5 shows the results for both areas for all three serotypes for the scenarios shown in Figure 3c . Figure A6 shows that some variability in the IPV take rate does not significantly impact the results and that the timing of OPV2 cessation (e.g., in 2015 instead of 2016) shifts the starting point of the drop in population immunity. Figure A7 shows the EIPM of reference case compared to the threshold EIP* for both areas for all three serotypes.
Figure A1:
The impact of the hypothetical retrospective scenarios on population immunity in Western Uttar Pradesh (WUP) (a) type 1 scenarios in the top of Table 2 (b) type 2 scenarios in the top of Table 2 (c) type 3 scenarios in the top of Table 2 (d) type 1 scenarios in the middle of Table 2 (e) type 2 scenarios in the middle of Table 2 (f) type 3 scenarios in the middle of Table 2 Figure A2: The impact of selected prospective scenarios on population immunity in Western Uttar Pradesh (WUP) (a) type 1, scenarios in the top of Table 3 (b) type 2, scenarios in the top of Table 3 (c) type 3, scenarios in the top of Table 3 (d) type 1, scenarios in the top of Table 3 Figure 
